id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-3547-0006,FDA,FDA-2017-E-3547,"Determination of Regulatory Review Period for Purposes of Patent
Extension; EXABLATE NEURO MODEL 4000 TYPE 1.0 SYSTEM",Notice,Determinations,2018-12-04T05:00:00Z,2018,12,2018-12-04T05:00:00Z,2019-02-05T04:59:59Z,2018-12-04T14:30:50Z,2018-26282,0,0,0900006483939723
FDA-2017-E-3547-0005,FDA,FDA-2017-E-3547,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-11-20T05:00:00Z,2018,11,2018-11-20T05:00:00Z,,2018-11-20T14:05:44Z,,0,0,09000064838ec3f3
FDA-2017-E-3547-0004,FDA,FDA-2017-E-3547,Letter from U.S. Patent and Trademark Office to  FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T16:18:18Z,,0,0,090000648378c897